<DOC>
	<DOCNO>NCT00017589</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody gemtuzumab ozogamicin locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Oblimersen may help gemtuzumab ozogamicin kill cancer cell make cancer cell sensitive drug . PURPOSE : Phase II trial study effectiveness combine oblimersen gemtuzumab ozogamicin treat old patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Oblimersen Gemtuzumab Ozogamicin Treating Older Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate elderly patient relapse CD33-positive acute myeloid leukemia treat oblimersen gemtuzumab ozogamicin . - Determine overall response rate duration response patient treat regimen . - Determine safety regimen patient . OUTLINE : This multicenter study . Patients receive oblimersen IV continuously day 1-7 15-22 gemtuzumab ozogamicin IV 2 hour day 4 18 . Patients follow monthly 6 month . PROJECTED ACCRUAL : A total 20-100 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD33+ acute myeloid leukemia ( AML ) In first relapse chemotherapy Complete response last least 3 month relapse No CNS leukemia No secondary leukemia history antecedent hematologic disorder prior initial onset AML ( e.g. , myelodysplasia ) PATIENT CHARACTERISTICS : Age : 60 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC le 30,000/mm^3 No bleed coagulation disorder except diseaserelated disseminate intravascular coagulation Hepatic : Bilirubin great 1.5 mg/dL PT PTT great 1.5 time upper limit normal OR INR great 1.3 No history chronic hepatitis cirrhosis Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled congestive heart failure No New York Heart Association class III IV heart disease Pulmonary : No severe pulmonary disease Other : HIV negative No concurrent medical disease would preclude study entry No known hypersensitivity phosphorothioatecontaining oligonucleotides , gemtuzumab ozogamicin component , E. coli protein , product produce E. coli No concurrent malignancy No known human antihuman antibodies No uncontrolled seizure disorder No active uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior allogeneic autologous stem cell transplantation No prior therapy antiCD33 antibody ( e.g. , gemtuzumab ozogamicin M195 ) Chemotherapy : See Disease Characteristics At least 2 week since prior cancer chemotherapy except intrathecal chemotherapy hydroxyurea Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior systemic radiotherapy Surgery : At least 2 week since prior major surgery No prior organ allograft Other : At least 3 week since prior antileukemic therapy recover No concurrent investigational therapy No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>